Dr. Candi S. Jump, D.O.
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
At a glance
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
SC license 37740 · PA license OT014519 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 16 payments worth $18,917 in total to this clinician.
| Alcresta Therapeutics, Inc. | $18,898 |
|---|---|
| Genzyme Corporation | $19.41 |
| Honoraria | $10,625 |
|---|---|
| Consulting Fee | $6,575 |
| Travel and Lodging | $1,308 |
| Food and Beverage | $409 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alcresta Therapeutics, Inc. Feb 4, 2025 | Consulting Fee RELIZORB · GASTROENTEROLOGY | $6,000 |
| Alcresta Therapeutics, Inc. Sep 17, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $4,025 |
| Alcresta Therapeutics, Inc. Dec 18, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $4,025 |
| Alcresta Therapeutics, Inc. Dec 2, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $2,000 |
| Alcresta Therapeutics, Inc. Nov 19, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL · in-kind | $638 |
| Alcresta Therapeutics, Inc. Nov 6, 2025 | Consulting Fee RELIZORB · GASTROENTEROLOGY | $575 |
| Alcresta Therapeutics, Inc. Dec 18, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $575 |
| Alcresta Therapeutics, Inc. Nov 19, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL · in-kind | $305 |
| Alcresta Therapeutics, Inc. Sep 17, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to COLUMBIA, SC | $175 |
| Alcresta Therapeutics, Inc. Dec 18, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL | $109 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alcresta Therapeutics, Inc. Dec 18, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $4,025 |
| Alcresta Therapeutics, Inc. Dec 18, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $575 |
| Alcresta Therapeutics, Inc. Dec 18, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL | $109 |
| Alcresta Therapeutics, Inc. Dec 2, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $2,000 |
| Alcresta Therapeutics, Inc. Nov 19, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL · in-kind | $638 |
| Alcresta Therapeutics, Inc. Nov 19, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL · in-kind | $305 |
| Alcresta Therapeutics, Inc. Nov 19, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to TAMPA, FL · in-kind | $80.00 |
| Alcresta Therapeutics, Inc. Nov 6, 2025 | Consulting Fee RELIZORB · GASTROENTEROLOGY | $575 |
| Alcresta Therapeutics, Inc. Sep 17, 2025 | Honoraria RELIZORB · GASTROENTEROLOGY | $4,025 |
| Alcresta Therapeutics, Inc. Sep 17, 2025 | Travel and Lodging RELIZORB · GASTROENTEROLOGY · travel to COLUMBIA, SC | $175 |
| Alcresta Therapeutics, Inc. Feb 4, 2025 | Consulting Fee RELIZORB · GASTROENTEROLOGY | $6,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,882 in research payments for these studies, mostly to the institutions running them.
- Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03196427
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.